MacroGenics/MGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About MacroGenics

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Ticker

MGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Scott Koenig

Employees

339

Headquarters

Rockville, United States

MacroGenics Metrics

BasicAdvanced
$256M
Market cap
-
P/E ratio
-$0.38
EPS
2.00
Beta
-
Dividend rate
$256M
2.00275
$21.88
$3.14
2.6M
3.633
3.61
-96.21%
-7.85%
-21.58%
-9.48%
5.908
2.41
2.413
-73.78%
74.70%
-17.57%

What the Analysts think about MacroGenics

Analyst Ratings

Majority rating from 12 analysts.
Buy

MacroGenics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-572.52% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.1M
-14.95%
Net income
-$52M
13.26%
Profit margin
-572.52%
33.18%

MacroGenics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 30.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.92
$0.28
-$0.75
-$0.84
-
Expected
-$0.52
-$0.10
-$0.15
-$0.64
-$0.63
Surprise
-276.51%
-392.89%
387.96%
30.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MacroGenics stock?

MacroGenics (MGNX) has a market cap of $256M as of June 18, 2024.

What is the P/E ratio for MacroGenics stock?

The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of June 18, 2024.

Does MacroGenics stock pay dividends?

No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next MacroGenics dividend payment date?

MacroGenics (MGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for MacroGenics?

MacroGenics (MGNX) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the MacroGenics stock price target?

The target price for MacroGenics (MGNX) stock is $10.8, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MacroGenics stock

Buy or sell MacroGenics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing